1Soran H,Younis N. Insulin detemir: a new basal insulin analogue. Diabete Obes Metab 2006 ;8( 1 ) :26 -30.
2Domhorst A, Luddeke H J, Sreenan S, et al. Safety and efficacy of insulin detemir in clinical practice: 14 - week follow - up data from type 1 and 2 diabetes patients in the PREDICTIVE European cohort. Int J Clin Pract 2007;61(3) :523 -528.
3Fuhlendorff J, Rorsman P, Kofod H, et al. Stimulation of insulin by release by repaglinide and glibenclam/de invoves both common and distinct processes. Diabetes 1998 ;41 ( 1 ) :534.
同被引文献27
1Yang W,Lu J,Weng J,et al.Prevalence of diabetes among men and women in China[J].N Engl J Med,2010,362(12):1090-1101.
2Soran H,Younis N.Insulin detemir:a new basal insulin analogue[J].Diabetes Obes Metab,2006,8(1):26-30.
3Dornhorst A,Lüddeke HJ,Honka M,et al.Safety and efficacy of insulin detemir basal-bolus therapy in type 1 diabetes patients:14-week data from the European cohort of the PREDICTIVE study[J].Curr Med Res Opin,2008,24(2):369-376.
4Dornhorst A,Lüddeke HJ,Sreenan S,et al.Safety and efficacy of insulin detemir in clinical practice:14-week follow-up data from type 1 and 2 diabetes patients in the PREDICTIVE European cohort[J].Int J Clin Pract,2007,61(3):523-528.
5Kurtzhals P,Sch(a)ffer L,Sφrensen A,et al.Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use[J].Diabetes,2000,49(6):999-1005.
6Meneghini LF, Rosenberg KH, Koenen C, et al. Insulin detemir im- proves glycaemic control with less hypoglycaemia and no weight gain in patients with type2diabetes who were insulin naive or treated with NPH or insulin glargine : clinical practice experience from a German subgroup of the PREDICTIVE study [ J ]. Diabetes Obesity and Metabolism, 2007.9 ( 3 ) .418 - 427.
